vs
Orthofix Medical Inc.（OFIX）与UNITIL CORP（UTL）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是UNITIL CORP的1.4倍（$219.9M vs $161.5M），UNITIL CORP净利率更高（11.8% vs -1.0%，领先12.8%），UNITIL CORP同比增速更快（26.7% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-36.3M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -4.9%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Unitil是一家跨州电力与天然气公用事业公司，业务覆盖美国新罕布什尔州、马萨诸塞州与缅因州。公司最早前身是1849年在缅因州成立的波特兰煤气灯公司，现企业主体于1984年设立，总部位于新罕布什尔州。目前公司总市值约6.8651亿美元，为约10.24万电力客户、超7.59万天然气客户提供服务。
OFIX vs UTL — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$161.5M
营收增速更快
UTL
高出24.7%
2.0%
净利率更高
UTL
高出12.8%
-1.0%
自由现金流更多
OFIX
多$53.1M
$-36.3M
两年增速更快
OFIX
近两年复合增速
-4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $161.5M |
| 净利润 | $-2.2M | $19.0M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 21.5% |
| 净利率 | -1.0% | 11.8% |
| 营收同比 | 2.0% | 26.7% |
| 净利润同比 | 92.4% | 21.8% |
| 每股收益（稀释后） | $-0.05 | $1.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXUTL
| Q4 25 | $219.9M | $161.5M | ||
| Q3 25 | $205.6M | $101.1M | ||
| Q2 25 | $203.1M | $102.6M | ||
| Q1 25 | $193.6M | $170.8M | ||
| Q4 24 | $215.7M | $127.5M | ||
| Q3 24 | $196.6M | $92.9M | ||
| Q2 24 | $198.6M | $95.7M | ||
| Q1 24 | $188.6M | $178.7M |
净利润OFIXUTL
| Q4 25 | $-2.2M | $19.0M | ||
| Q3 25 | $-22.8M | $-300.0K | ||
| Q2 25 | $-14.1M | $4.0M | ||
| Q1 25 | $-53.1M | $27.5M | ||
| Q4 24 | $-29.1M | $15.6M | ||
| Q3 24 | $-27.4M | $0 | ||
| Q2 24 | $-33.4M | $4.3M | ||
| Q1 24 | $-36.0M | $27.2M |
毛利率OFIXUTL
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXUTL
| Q4 25 | 0.2% | 21.5% | ||
| Q3 25 | -8.3% | 6.9% | ||
| Q2 25 | -7.9% | 13.0% | ||
| Q1 25 | -25.2% | 27.0% | ||
| Q4 24 | -5.3% | 22.1% | ||
| Q3 24 | -9.6% | 6.2% | ||
| Q2 24 | -12.5% | 13.0% | ||
| Q1 24 | -15.6% | 24.7% |
净利率OFIXUTL
| Q4 25 | -1.0% | 11.8% | ||
| Q3 25 | -11.1% | -0.3% | ||
| Q2 25 | -6.9% | 3.9% | ||
| Q1 25 | -27.4% | 16.1% | ||
| Q4 24 | -13.5% | 12.2% | ||
| Q3 24 | -13.9% | — | ||
| Q2 24 | -16.8% | 4.5% | ||
| Q1 24 | -19.1% | 15.2% |
每股收益（稀释后）OFIXUTL
| Q4 25 | $-0.05 | $1.05 | ||
| Q3 25 | $-0.57 | $-0.02 | ||
| Q2 25 | $-0.36 | $0.25 | ||
| Q1 25 | $-1.35 | $1.69 | ||
| Q4 24 | $-0.76 | $0.97 | ||
| Q3 24 | $-0.71 | $0.00 | ||
| Q2 24 | $-0.88 | $0.27 | ||
| Q1 24 | $-0.95 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $15.6M |
| 总债务越低越好 | — | $670.5M |
| 股东权益账面价值 | $450.0M | $609.6M |
| 总资产 | $850.6M | $2.1B |
| 负债/权益比越低杠杆越低 | — | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资OFIXUTL
| Q4 25 | $82.0M | $15.6M | ||
| Q3 25 | $62.9M | $14.6M | ||
| Q2 25 | $65.6M | $8.5M | ||
| Q1 25 | $58.0M | $10.2M | ||
| Q4 24 | $83.2M | $6.3M | ||
| Q3 24 | $30.1M | $6.3M | ||
| Q2 24 | $26.4M | $2.8M | ||
| Q1 24 | $27.0M | $6.3M |
总债务OFIXUTL
| Q4 25 | — | $670.5M | ||
| Q3 25 | $157.2M | $670.5M | ||
| Q2 25 | $157.0M | $640.7M | ||
| Q1 25 | $156.9M | $642.1M | ||
| Q4 24 | $157.0M | $643.3M | ||
| Q3 24 | $118.5M | $643.3M | ||
| Q2 24 | $118.0M | $511.3M | ||
| Q1 24 | $118.2M | $512.8M |
股东权益OFIXUTL
| Q4 25 | $450.0M | $609.6M | ||
| Q3 25 | $442.5M | $597.2M | ||
| Q2 25 | $458.3M | $532.8M | ||
| Q1 25 | $458.3M | $534.1M | ||
| Q4 24 | $503.1M | $512.5M | ||
| Q3 24 | $525.9M | $502.4M | ||
| Q2 24 | $546.0M | $508.8M | ||
| Q1 24 | $570.3M | $510.8M |
总资产OFIXUTL
| Q4 25 | $850.6M | $2.1B | ||
| Q3 25 | $832.6M | $1.9B | ||
| Q2 25 | $837.2M | $1.9B | ||
| Q1 25 | $823.1M | $1.9B | ||
| Q4 24 | $893.3M | $1.8B | ||
| Q3 24 | $867.9M | $1.7B | ||
| Q2 24 | $882.0M | $1.7B | ||
| Q1 24 | $906.0M | $1.7B |
负债/权益比OFIXUTL
| Q4 25 | — | 1.10× | ||
| Q3 25 | 0.36× | 1.12× | ||
| Q2 25 | 0.34× | 1.20× | ||
| Q1 25 | 0.34× | 1.20× | ||
| Q4 24 | 0.31× | 1.26× | ||
| Q3 24 | 0.23× | 1.28× | ||
| Q2 24 | 0.22× | 1.00× | ||
| Q1 24 | 0.21× | 1.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $21.4M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-36.3M |
| 自由现金流率自由现金流/营收 | 7.6% | -22.5% |
| 资本支出强度资本支出/营收 | 4.9% | 35.7% |
| 现金转化率经营现金流/净利润 | — | 1.13× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-53.8M |
8季度趋势，按日历期对齐
经营现金流OFIXUTL
| Q4 25 | $27.7M | $21.4M | ||
| Q3 25 | $12.4M | $15.6M | ||
| Q2 25 | $11.6M | $42.2M | ||
| Q1 25 | $-18.4M | $52.1M | ||
| Q4 24 | $23.7M | $23.3M | ||
| Q3 24 | $11.7M | $26.1M | ||
| Q2 24 | $9.0M | $49.9M | ||
| Q1 24 | $-18.6M | $26.6M |
自由现金流OFIXUTL
| Q4 25 | $16.8M | $-36.3M | ||
| Q3 25 | $2.5M | $-39.0M | ||
| Q2 25 | $4.5M | $2.0M | ||
| Q1 25 | $-25.1M | $19.5M | ||
| Q4 24 | $15.2M | $-32.3M | ||
| Q3 24 | $6.3M | $-31.3M | ||
| Q2 24 | $-360.0K | $13.2M | ||
| Q1 24 | $-29.1M | $6.4M |
自由现金流率OFIXUTL
| Q4 25 | 7.6% | -22.5% | ||
| Q3 25 | 1.2% | -38.6% | ||
| Q2 25 | 2.2% | 1.9% | ||
| Q1 25 | -13.0% | 11.4% | ||
| Q4 24 | 7.0% | -25.3% | ||
| Q3 24 | 3.2% | -33.7% | ||
| Q2 24 | -0.2% | 13.8% | ||
| Q1 24 | -15.4% | 3.6% |
资本支出强度OFIXUTL
| Q4 25 | 4.9% | 35.7% | ||
| Q3 25 | 4.8% | 54.0% | ||
| Q2 25 | 3.5% | 39.2% | ||
| Q1 25 | 3.5% | 19.1% | ||
| Q4 24 | 4.0% | 43.6% | ||
| Q3 24 | 2.7% | 61.8% | ||
| Q2 24 | 4.7% | 38.3% | ||
| Q1 24 | 5.6% | 11.3% |
现金转化率OFIXUTL
| Q4 25 | — | 1.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 10.55× | ||
| Q1 25 | — | 1.89× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 11.60× | ||
| Q1 24 | — | 0.98× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
UTL
暂无分部数据
